All In Biotech

Free tool

FAERS Monitor: Likmez

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216755 or its brand name (Likmez, Metronidazole). Reports on generic versions are filed under their own applications.

Reports

23

Serious

18

78% of reports

Hospitalization

18

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • toxic encephalopathy4
  • balance disorder2
  • diplopia2
  • drug ineffective2
  • encephalopathy2
  • posterior reversible encephalopathy syndrome2
  • product taste abnormal2
  • septic shock2
  • vomiting2
  • ataxia1
  • bipolar i disorder1
  • bowel movement irregularity1
  • central vision loss1
  • cerebellar ataxia1
  • disseminated intravascular coagulation1

Reports by year received

View as table
YearReports
20201
202412
20254
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
central vision loss14123.4603.71,025
cerebellar ataxia1956.5140.5238
toxic encephalopathySignal4722.6296.42,205
bipolar i disorder1417.061.3103
posterior reversible encephalopathy syndrome2191.651.0213
product taste abnormal2135.135.9149
bowel movement irregularity1119.417.629
ataxia177.111.318
encephalopathy274.519.881
diplopia270.418.776
disseminated intravascular coagulation165.09.615
septic shock242.011.244
balance disorder221.25.621
vomiting23.91.02
drug ineffective21.40.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.